Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease
Open Access
- 10 November 2016
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 74 (6) , 1153-1163
Abstract
Glycogen synthase kinase-3β (GSK-3β) is a serine-threonine kinase implicated in multiple processes and signaling pathways. Its dysregulation is associated with different pathological conditions including Alzheimer’s disease (AD). Here we demonstrate how changes in GSK-3β activity and/or levels regulate the production and subsequent secretion of fractalkine, a chemokine involved in the immune response that has been linked to AD and to other different neurological disorders. Treatment of primary cultured neurons with GSK-3β inhibitors such as lithium and AR-A014418 decreased full-length fractalkine in total cell extracts. Opposite effects were observed after neuron transduction with a lentiviral vector overexpressing the kinase. Biotinylation assays showed that those changes mainly affect the plasma membrane-associated form of the protein, an observation that positively correlates with changes in the levels of its soluble form. These effects were confirmed in lithium-treated wild type (wt) mice and in GSK-3β transgenic animals, as well as in brain samples from AD patients, evident as age-dependent (animals) or Braak stage dependent changes (humans) in both the membrane-bound and the soluble forms of the protein. Further immunohistochemical analyses demonstrated how GSK-3β exerts these effects by affecting the trafficking of the chemokine from the Golgi to the plasma membrane, in different and opposite ways when the levels/activity of the kinase are increased or decreased. This work provides for the first time a mechanism linking GSK-3β and fractalkine both in vitro and in vivo, with important implications for neurological disorders and especially for AD, in which levels of this chemokine might be useful as a diagnostic tool.Keywords
Funding Information
- Spanish Ministry of Economy and Competitiveness (SAF 2006-02424, BFU-2008-03980, BFU-2010-21507)
- Consejería de Sanidad, Comunidad de Madrid (SAL/0202/2006)
- Fundacion M. Botin
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
- Fundación Ramón Areces
This publication has 39 references indexed in Scilit:
- Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disordersNeuropsychiatric Disease and Treatment, 2013
- Role of Rab GTPases in Membrane Traffic and Cell PhysiologyPhysiological Reviews, 2011
- The Golgi apparatus: an organelle with multiple complex functionsBiochemical Journal, 2010
- CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse ModelsThe American Journal of Pathology, 2010
- Golgi-associated GSK3β regulates the sorting process of post-Golgi membrane traffickingJournal of Cell Science, 2010
- Regulation of Tau Pathology by the Microglial Fractalkine ReceptorNeuron, 2010
- Interactions between ChemokinesJournal of Biological Chemistry, 2010
- CX3CR1 Is Expressed by Human B Lymphocytes and Meditates CX3CL1 Driven Chemotaxis of Tonsil CentrocytesPLOS ONE, 2009
- The role of microtubule actin cross-linking factor 1 (MACF1) in the Wnt signaling pathwayGenes & Development, 2006
- The glamour and gloom of glycogen synthase kinase-3Trends in Biochemical Sciences, 2004